Anti-HIV Designer T Cells Progressively Eradicate a Latently Infected Cell Line by Sequentially Inducing HIV Reactivation then Killing the Newly Gp120-positive Cells

Overview

Journal Virology

Specialty Microbiology

Date 2013 Oct 1

PMID 24074590

Citations 30

Authors

Gautam K Sahu

Kaori Sango

Nithianandan Selliah

Qiangzhong Ma

Gail Skowron

Richard P Junghans

Affiliations

Soon will be listed here.

Abstract

The current antiretroviral therapy (ART) can effectively reduce plasma HIV loads to undetectable levels, but cannot eliminate latently infected resting memory CD4 T cells that persist for the lifetime of infected patients. Therefore, designing new therapeutic approaches to eliminate these latently infected cells or the cells that produce HIV upon reactivation from latency is a priority in the ART era in order to progress to a cure of HIV. Here, we show that "designer" T cells expressing chimeric antigen receptor (CAR), CD4-CD28-CD3ζ, can target and kill HIV Env-expressing cells. Further, they secrete effector cytokines upon contact with HIV Env+ target cells that can reactivate latent HIV in a cell line model, thereby exposing those cells to recognition and killing by anti-HIV CAR+ T cells. Taken to the limit, this process could form the basis for an eventual functional or sterilizing cure for HIV in patients.

Citing Articles

Extracellular domain, hinge, and transmembrane determinants affecting surface CD4 expression of a novel anti-HIV chimeric antigen receptor (CAR) construct.

Zenere G, Wu C, Midkiff C, Johnson N, Grice C, Wimley W PLoS One. 2024; 19(8):e0293990.

PMID: 39133676 PMC: 11318886. DOI: 10.1371/journal.pone.0293990.

Chimeric antigen receptors enable superior control of HIV replication by rapidly killing infected cells.

Zhou Y, Jadlowsky J, Baiduc C, Klattenhoff A, Chen Z, Bennett A PLoS Pathog. 2023; 19(12):e1011853.

PMID: 38100526 PMC: 10773964. DOI: 10.1371/journal.ppat.1011853.

Extracellular domain, hinge, and transmembrane determinants affecting surface CD4 expression of a novel anti-HIV chimeric antigen receptor (CAR) construct.

Zenere G, Wu C, Midkiff C, Johnson N, Grice C, Wimley W bioRxiv. 2023; .

PMID: 37961145 PMC: 10634810. DOI: 10.1101/2023.10.25.563930.

CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection.

Pampusch M, Abdelaal H, Cartwright E, Molden J, Davey B, Sauve J PLoS Pathog. 2022; 18(2):e1009831.

PMID: 35130312 PMC: 8853520. DOI: 10.1371/journal.ppat.1009831.

HIV-1-Specific CAR-T Cells With Cell-Intrinsic PD-1 Checkpoint Blockade Enhance Anti-HIV Efficacy .

Jiang Z, Liang H, Pan H, Liang Y, Wang H, Yang X Front Microbiol. 2021; 12:684016.

PMID: 34295319 PMC: 8290485. DOI: 10.3389/fmicb.2021.684016.

References

Fu X, Karr R . HLA-DR alpha chain residues located on the outer loops are involved in nonpolymorphic and polymorphic antibody-binding epitopes. Hum Immunol. 1994; 39(4):253-60. DOI: 10.1016/0198-8859(94)90268-2. View

Wang R, Wang X, ATWOOD A, Topalian S, Rosenberg S . Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science. 1999; 284(5418):1351-4. DOI: 10.1126/science.284.5418.1351. View

Tyagi M, Pearson R, Karn J . Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J Virol. 2010; 84(13):6425-37. PMC: 2903277. DOI: 10.1128/JVI.01519-09. View

Boise L, Minn A, Noel P, June C, Accavitti M, LINDSTEN T . CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity. 1995; 3(1):87-98. DOI: 10.1016/1074-7613(95)90161-2. View

Folks T, Clouse K, Justement J, Rabson A, Duh E, Kehrl J . Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci U S A. 1989; 86(7):2365-8. PMC: 286913. DOI: 10.1073/pnas.86.7.2365. View

Lambotte O, Taoufik Y, de Goer M, Wallon C, Goujard C, Delfraissy J . Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2000; 23(2):114-9. DOI: 10.1097/00126334-200002010-00002. View

Lasky L, Nakamura G, Smith D, Fennie C, Shimasaki C, Patzer E . Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell. 1987; 50(6):975-85. DOI: 10.1016/0092-8674(87)90524-1. View

Clouse K, Powell D, Washington I, Poli G, Strebel K, Farrar W . Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol. 1989; 142(2):431-8. View

Haynes N, Trapani J, Teng M, Jackson J, Cerruti L, Jane S . Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol. 2002; 169(10):5780-6. DOI: 10.4049/jimmunol.169.10.5780. View

10.

Hammer S, Squires K, Hughes M, Grimes J, Demeter L, Currier J . A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997; 337(11):725-33. DOI: 10.1056/NEJM199709113371101. View

11.

Green J, Noel P, Sperling A, Walunas T, Lenschow D, Stack R . T cell costimulation through the CD28 receptor. Proc Assoc Am Physicians. 1995; 107(1):41-6. View

12.

Wong J, Hezareh M, Gunthard H, Havlir D, Ignacio C, Spina C . Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997; 278(5341):1291-5. DOI: 10.1126/science.278.5341.1291. View

13.

Song S, Li H, Cloyd M . Rates of shutdown of HIV-1 into latency: roles of the LTR and tat/rev/vpu gene region. Virology. 1996; 225(2):377-86. DOI: 10.1006/viro.1996.0612. View

14.

Beaudoin E, Bais A, Junghans R . Sorting vector producer cells for high transgene expression increases retroviral titer. J Virol Methods. 2008; 148(1-2):253-9. DOI: 10.1016/j.jviromet.2007.12.008. View

15.

Mitsuyasu R, Anton P, Deeks S, Scadden D, Connick E, Downs M . Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood. 2000; 96(3):785-93. View

16.

Rosok B, Voltersvik P, Larsson B, Albert J, Brinchmann J, Asjo B . CD8+ T cells from HIV type 1-seronegative individuals suppress virus replication in acutely infected cells. AIDS Res Hum Retroviruses. 1997; 13(1):79-85. DOI: 10.1089/aid.1997.13.79. View

17.

Thali M, Olshevsky U, Furman C, Gabuzda D, Li J, Sodroski J . Effects of changes in gp120-CD4 binding affinity on human immunodeficiency virus type 1 envelope glycoprotein function and soluble CD4 sensitivity. J Virol. 1991; 65(9):5007-12. PMC: 248964. DOI: 10.1128/JVI.65.9.5007-5012.1991. View

18.

Luzuriaga K, Bryson Y, Krogstad P, Robinson J, Stechenberg B, Lamson M . Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med. 1997; 336(19):1343-9. DOI: 10.1056/NEJM199705083361902. View

19.

Bagasra O, Lavi E, Bobroski L, Khalili K, Pestaner J, Tawadros R . Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry. AIDS. 1996; 10(6):573-85. DOI: 10.1097/00002030-199606000-00002. View

20.

Emtage P, Lo A, Gomes E, Liu D, Gonzalo-Daganzo R, Junghans R . Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation. Clin Cancer Res. 2008; 14(24):8112-22. PMC: 2659496. DOI: 10.1158/1078-0432.CCR-07-4910. View